During injury or infection, our body’s immune system protects us by launching inflammation. But uncontrolled inflammation drives common diseases such as cancer, diabetes and Alzheimer’s. This project will reveal how the body produces interleukin-1? – a protein at the heart of inflammation and disease – so we can design better strategies for treating patients with inflammation-driven disease.
Inhibition Of Necroptosis As A Novel Strategy For The Prevention Of Bronchiolitis And Subsequent Asthma
Funder
National Health and Medical Research Council
Funding Amount
$658,015.00
Summary
Severe virus associated bronchiolitis is a major cause of infant mortality and a risk factor for asthma. Using a mouse model, we have shown that virus infection causes tissue damage, leading to the release of 'danger' molecules that promote excessive inflammation and tissue remodelling. We have identified an important mechanism by which the danger molecules are released. We will now assess whether blocking this process ameliorates viral bronchiolitis and breaks its nexus with subsequent asthma.
Excess inflammation is a major problem after injury and in many diseases. Upon injury molecules are release that act as danger signals to alert the immune system to start the repair process. However, high levels of these dangers signals can impair the final stages of healing. Understanding how to prevent the immune system being excessively stimulated by these danger signals is key to being able to dampen inflammation after injury improve the healing response.
The innate immune response is our primary defence against infection, but must be controlled carefully to avoid chronic inflammation and autoimmunity. Studying tiny regulators of gene function called micro-RNAs and unique cellular pathways, we aim to understand the “big picture” of genetic regulatory systems in innate immunity to provide new insights into inflammation and infection, the genetic basis of diseases, and to identify new potential therapeutic targets, biomarkers and antiviral targets.
A Systems-biology Approach To Understanding The Beneficial Heterologous Effects Of Neonatal BCG Vaccination In A Melbourne-based Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$846,853.00
Summary
BCG vaccine (usually used to protect against TB) also enhances the immune system of young babies to protect them against infections other than TB. We have a large collection of blood samples from a study in which babies were randomised to be given BCG vaccine at birth or no BCG. We will use these to understand the immunological and molecular mechanisms by which BCG boosts the immune system to protect against infections other than TB.